Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia.
about
Preventing stem cell transplantation-associated viral infections using T-cell therapyT-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effectHigh-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cellsCytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma.NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine.Immunotherapy of human cancers using gene modified T lymphocytes.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell TransplantatioPRAME is a golgi-targeted protein that associates with the Elongin BC complex and is upregulated by interferon-gamma and bacterial PAMPsGeneration of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia--implications for immunotherapy.Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor.Common Ewing sarcoma-associated antigens fail to induce natural T cell responses in both patients and healthy individuals.Survivin-specific T cell receptor targets tumor but not T cells.Genetic modification of human T lymphocytes for the treatment of hematologic malignancies.New insights into antigen specific immunotherapy for chronic myeloid leukemiaThe role of peptide and DNA vaccines in myeloid leukemia immunotherapyAugmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation.Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia.Adoptive Immunotherapy For Leukemia With Ex vivo Expanded T Cells.Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes.The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells.The biological basis for immunotherapy in patients with chronic myelogenous leukemia.Wilms tumor 1 peptide vaccination after hematopoietic stem cell transplant in leukemia patients.The allogeneic graft-versus-cancer effect.Generation of V α13/β21+T cell specific target CML cells by TCR gene transfer.Designing T cells for cancer immunotherapyImmunotherapy of chronic myeloid leukemia: present state and future prospects.Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia.Vaccines as consolidation therapy for myeloid leukemia.Peptide vaccine therapy for leukemia.Is antigen specificity the key to efficient adoptive T-cell therapy?Biological therapy and the immune system in patients with chronic myeloid leukemia.Vaccination strategies to improve outcome of hematopoietic stem cell transplant in leukemia patients: early evidence and future prospects.Immunology of chronic myeloid leukemia: current concepts and future goals.Chronic Myeloid Leukemia: Immunobiology and Novel Immunotherapeutic Approaches.A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens.Naive tumour-specific CD4+ T cells were efficiently primed in acute lymphoblastic leukaemia.The immunogenicity of virus-derived 2A sequences in immunocompetent individuals.Characterization of Ewing sarcoma associated cancer/testis antigensActivated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens.
P2860
Q26801365-3D37DFA0-CDC3-4DD5-9B15-64D072D575DEQ26826830-84066C84-F6A2-4259-A68A-A54AD16F4104Q33806895-FE0132E6-1B53-45A2-A1E3-9D419562F11FQ34018782-120207F9-9D31-4DAA-B1A4-BBB02BF7C141Q34182308-FB500E60-02DC-4E84-899D-F4C29C4D99F4Q34188383-BA4ADB6F-7B39-4FF6-8597-F6444F9D38B7Q34202277-925AAC74-B3C5-4A9B-AD20-A4361F0B2DF6Q34608912-46925C84-FB81-43F1-BC53-8F3B05B5B0C4Q34803707-48604D16-6BE8-428D-A993-8CCF4C9A52B1Q34935239-CD40C523-7EE2-46AF-B799-BDCE6D8BBEA8Q35001579-6A731CA2-5C4C-4B89-8D4A-3131B5DF6D8BQ35196739-33CE9415-4921-498B-90EE-E09DA6C956E3Q35242576-5CCF8E53-EEC8-439C-827B-B5AB5F92A308Q36366557-12495392-CC76-4456-A898-92850C45BDB2Q36513477-69C094B9-1C0C-4EAA-B570-3315A6B66881Q36608571-9B01C8E3-6632-4445-8A62-4A445268B0FCQ36662079-677DFAE6-01FA-4C20-9FDA-35731AFDA820Q37119922-9C8286DC-452A-4555-B3AF-3BDA98C88C5FQ37242561-E8B44D52-53FE-42CC-B888-62109732ADE7Q37334642-75DDCFF0-02A9-4256-8824-3072337CB893Q37381700-9D318668-E2AF-4AEB-8DDD-0324F4A8DBB3Q37428671-2ED16211-8383-43F2-81C6-D09CB9D62DF5Q37574653-AE74EB18-45DE-4A4B-8B2C-FE1DD2B3DDBEQ37593125-E81BF892-3C86-453C-92AC-8C799F8E772AQ37708939-76F75106-9CE6-4426-89D2-45814E77ECDAQ37737817-82F69F9F-4342-4DAF-951F-C610D133CFC3Q37773256-4CDB6B51-8BFE-46BF-88DB-52308589CDB9Q37783631-FF441155-E263-47C9-8723-040D47B126ADQ37842342-BE61BBCC-EE51-4857-9DE0-A039AB4C6E7AQ37850382-69CC46FA-B867-4863-9BFC-F95D30537D39Q37861214-86CEA084-0CDF-457C-88E8-EB64C11464B9Q38015742-5976B71B-880B-45CF-BCBD-EEF944367731Q38245948-DA598045-7B9C-4137-96F2-A9071C27809BQ38366539-39A00C51-9FBB-490B-A5B0-8E203126C2DEQ38684223-43FA3AD5-C9B0-4B0D-BEB5-94E75EA735F1Q38719407-BE223866-1D6D-4BD7-AFB0-E7570060E49EQ38986891-C37E4D4A-C571-40A5-A52E-B8B123E920F4Q39148534-BF6A50F5-A329-4A5B-A9D3-C63CB940E9A0Q39215865-B2C141E8-999C-4D83-A061-2995D2265AB8Q39472050-B6EA5013-12EA-4FDF-9A43-ABD717B5F4B2
P2860
Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Cytotoxic T lymphocytes direct ...... rget chronic myeloid leukemia.
@en
Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma
@nl
type
label
Cytotoxic T lymphocytes direct ...... rget chronic myeloid leukemia.
@en
Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma
@nl
prefLabel
Cytotoxic T lymphocytes direct ...... rget chronic myeloid leukemia.
@en
Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma
@nl
P2093
P2860
P921
P1433
P1476
Cytotoxic T lymphocytes direct ...... rget chronic myeloid leukemia.
@en
P2093
Barbara Savoldo
Biagio De Angelis
Cliona M Rooney
Concetta Quintarelli
Fabrizio Pane
Gianpietro Dotti
Helen E Heslop
Luigia Luciano
Martha Mims
Valentina Hoyos
P2860
P304
P356
10.1182/BLOOD-2008-04-150045
P407
P577
2008-06-30T00:00:00Z